Male fertility rates are dropping and yet women in heterosexual relationships are still carrying the burden. Here's what ...
Zacks Investment Research on MSN
Hims & Hers plunges 29.1% in 6 months: Time to hold the stock or sell?
Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term losses from the stock lately, despite its ...
More women are asking about testosterone therapy. Here’s what the science shows, the risks to know, and who may benefit from ...
News-Medical.Net on MSN
Research ushers in a new era of hope for patients with primary immune thrombocytopenia
More than half of patients in a Phase III clinical trial who received a limited course of the experimental monoclonal antibody ianalumab for primary immune thrombocytopenia (ITP), an autoimmune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback